Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0036-1579624
Seronegative Maternal Ocular Myasthenia Gravis and Delayed Transient Neonatal Myasthenia Gravis
Publication History
14 December 2015
27 January 2016
Publication Date:
16 March 2016 (online)
![](https://www.thieme-connect.de/media/ajpr/201601/lookinside/thumbnails/10-1055-s-0036-1579624_150084-1.jpg)
Abstract
Background Myasthenia gravis (MG) is an autoimmune disorder with fluctuating muscle weakness, divided into generalized and localized (ocular) forms. Maternal antibodies to acetylcholine receptors cross the placenta and may cause transient neonatal myasthenia gravis (TNMG). We present a case of seronegative maternal ocular MG and delayed TNMG.
Case A 29-year-old G3P1011 underwent cesarean birth of a male infant who developed oxygen desaturation requiring supplemental oxygen on day of life (DOL) 3. Based on the clinical course and after exclusion of other diagnoses, the infant was diagnosed with TNMG. Infant's condition improved spontaneously and he was weaned off supplemental oxygen and discharged home on DOL 12.
Conclusion Infants born to mothers with seronegative localized (ocular) MG are also susceptible to TNMG which may be late in onset.
-
References
- 1 Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330 (25) 1797-1810
- 2 Plauché WC. Myasthenia gravis in mothers and their newborns. Clin Obstet Gynecol 1991; 34 (1) 82-99
- 3 Kalidindi M, Ganpot S, Tahmesebi F, Govind A, Okolo S, Yoong W. Myasthenia gravis and pregnancy. J Obstet Gynaecol 2007; 27 (1) 30-32
- 4 Da Silva FC, do Cima LC, de Sá RAM. Myasthenia gravis and pregnancy. In: Minagar A, ed. Neurological Disorders and Pregnancy. Burlington, MA: Elsevier; 2011: 55-68
- 5 Papazian O. Transient neonatal myasthenia gravis. J Child Neurol 1992; 7 (2) 135-141
- 6 Creasy RK, Resnik R, Greene MF, Iams JD, Lockwood CJ ; Maternal Fetal Medicine: Principles and Practice. Ch 52, pg 1108-1109. Philadelphia, PA. Seventh edition. 2014
- 7 Djelmis J, Sostarko M, Mayer D, Ivanisevic M. Myasthenia gravis in pregnancy: report on 69 cases. Eur J Obstet Gynecol Reprod Biol 2002; 104 (1) 21-25
- 8 Merlob P, Litwin A, Mor N. Possible association between acetazolamide administration during pregnancy and metabolic disorders in the newborn. Eur J Obstet Gynecol Reprod Biol 1990; 35 (1) 85-88
- 9 Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun 2014; 48–49: 143-148
- 10 Norwood F, Dhanjal M, Hill M , et al. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. J Neurol Neurosurg Psychiatry 2014; 85 (5) 538-543
- 11 Sommer N, Melms A, Weller M, Dichgans J. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects. Doc Ophthalmol 1993; 84 (4) 309-333
- 12 Bever Jr CT, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol 1983; 14 (5) 516-519
- 13 Zisimopoulou P, Brenner T, Trakas N, Tzartos SJ. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 2013; 12 (9) 924-930
- 14 Zisimopoulou P, Evangelakou P, Tzartos J , et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 2014; 52: 139-145
- 15 Tsivgoulis G, Dervenoulas G, Kokotis P , et al. Double seronegative myasthenia gravis with low density lipoprotein-4 (LRP4) antibodies presenting with isolated ocular symptoms. J Neurol Sci 2014; 346 (1–2) 328-330